title: The effect of tamoxifen and raloxifene on estrogen metabolism and endometrial cancer risk.
abstract: Selective estrogen receptor modulators (SERMs) demonstrate differential endometrial cancer (EC) risk. While tamoxifen (TAM) use increases the risk of endometrial hyperplasia and malignancy, raloxifene (RAL) has neutral effects on the uterus. How TAM increases the risk of EC and why TAM and RAL differentially modulate the risk for EC, however, remain elusive. Here, we tested the hypothesis that TAM increases the risk for EC, at least in part, by enhancing the local estrogen biosynthesis and directing estrogen metabolism towards the formation of genotoxic and hormonally active estrogen metabolites. In addition, the differential effects of TAM and RAL in EC risk are attributed to their differential effect on estrogen metabolism/metabolites. The endometrial cancer cell line (Ishikawa cells) and the nonmalignant immortalized human endometrial glandular cell line (EM1) were used for the study. The profile of estrogen/estrogen metabolites (EM), depurinating estrogen-DNA adducts, and the expression of estrogen-metabolizing enzymes in cells treated with 17β-estradiol (E2) alone or in combination with TAM or RAL were investigated using high performance liquid chromatography-electrospray ionization-tandem mass spectrometry (HPLC-ESI-MS(2)), ultraperformance liquid chromatography/tandem mass spectrometry (UPLC-MS/MS), and Western blot analysis, respectively. TAM significantly increased the total EM and enhanced the formation of hormonally active and carcinogenic estrogen metabolites, 4-hydroxestrone (4-OHE1) and 16α-hydroxyestrone, with concomitant reduction in the formation of antiestrogenic and anticarcinogenic 2-hydroxyestradiol and 2-methoxyestradiol. Furthermore, TAM increased the formation of depurinating estrogen-DNA adducts 4-OHE1 [2]-1-N7Guanine and 4-OHE1 [2]-1-N3 Adenine. TAM-induced alteration in EM and depurinating DNA adduct formation is associated with altered expression of estrogen metabolizing enzymes CYP1A1, CYP1B1, COMT, NQO1, and SF-1 as revealed by Western blot analysis. In contrast to TAM, RAL has minimal effect on EM, estrogen-DNA adduct formation, or estrogen-metabolizing enzymes expression. These data show that TAM perturbs the balance of estrogen-metabolizing enzymes and alters the disposition of estrogen metabolites, which can explain, at least in part, the mechanism for TAM-induced EC. These results also implicate the differential effect of TAM and RAL on estrogen metabolism/metabolites as a potential mechanism for their disparate effects on the endometrium.
authors: Department of Obstetrics & Gynecology, University of Texas Medical Branch, Galveston, United States. mywillia@utmb.edu
authors: Marian Y
authors: MY
authors: Williams-Brown
authors: Sana M
authors: SM
authors: Salih
authors: Xia
authors: X
authors: Xu
authors: Timothy D
authors: TD
authors: Veenstra
authors: Muhammad
authors: M
authors: Saeed
authors: Shaleen K
authors: SK
authors: Theiler
authors: Concepcion R
authors: CR
authors: Diaz-Arrastia
authors: Salama A
authors: SA
authors: Salama
references: J Clin Oncol. 2008 Sep 1;26(25):4151-9
references: 18757329
references: J Biol Chem. 2004 Jun 25;279(26):27008-16
references: 15090535
references: Obstet Gynecol. 2004 Aug;104(2):255-60
references: 15291996
references: Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14
references: 9484623
references: Cancer Res. 1996 Apr 1;56(7):1475-9
references: 8603387
references: Science. 2002 Mar 29;295(5564):2380-1
references: 11923515
references: Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):357-66
references: 15734958
references: Mutagenesis. 2009 Sep;24(5):391-404
references: 19505894
references: Drug Metab Dispos. 2008 May;36(5):946-54
references: 18299335
references: Br J Cancer. 2008 Oct 7;99(7):1056-63
references: 18797454
references: Biochem Mol Biol Int. 1998 Jul;45(4):775-81
references: 9713701
references: Cancer Chemother Pharmacol. 2009 Jun;64(1):35-43
references: 18839173
references: Gynecol Oncol. 2004 Aug;94(2):256-66
references: 15297160
references: J Natl Cancer Inst. 2004 Jul 21;96(14):1099-104
references: 15265972
references: Ann N Y Acad Sci. 2009 Feb;1155:237-41
references: 19250210
references: Oncogene. 2008 Oct 23;27(49):6376-84
references: 18663360
references: Drug Metab Rev. 2004 May;36(2):199-218
references: 15237851
references: Carcinogenesis. 2000 Aug;21(8):1461-7
references: 10910945
references: Reprod Biol Endocrinol. 2010 Aug 02;8:93
references: 20678202
references: Chem Res Toxicol. 2004 Dec;17(12):1577-83
references: 15606132
references: Gynecol Oncol. 2005 Jan;96(1):25-31
references: 15589576
references: Clin Cancer Res. 2006 Sep 15;12(18):5603
references: 17000698
references: Cancer Res. 1996 Oct 1;56(19):4374-7
references: 8813128
references: Carcinogenesis. 1998 Jan;19(1):1-27
references: 9472688
references: Proc Natl Acad Sci U S A. 1985 Sep;82(18):6295-9
references: 2994069
references: Climacteric. 2007 Oct;10 Suppl 2:62-5
references: 17882675
references: Oncogene. 2004 Apr 1;23(14):2442-53
references: 14676828
references: Front Biosci. 2005 May 01;10:1440-61
references: 15769636
references: Free Radic Biol Med. 2008 Jul 15;45(2):136-45
references: 18423413
references: Chem Res Toxicol. 1999 Jul;12(7):646-53
references: 10409405
references: Carcinogenesis. 2000 Apr;21(4):845-7
references: 10753226
references: Mol Biol Cell. 2004 Mar;15(3):1262-72
references: 14699072
references: Cancer Res. 2004 May 1;64(9):3119-25
references: 15126349
references: J Steroid Biochem Mol Biol. 1993 May;45(5):383-90
references: 8388710
references: J Biol Chem. 1999 Feb 5;274(6):3430-8
references: 9920887
references: Int J Cancer. 1997 Nov 4;73(3):381-91
references: 9359486
references: Nucleic Acids Res. 2008 Oct;36(18):5933-45
references: 18805907
references: Anticancer Res. 2002 May-Jun;22(3):1475-80
references: 12168826
references: Carcinogenesis. 1999 Feb;20(2):339-42
references: 10069474
references: Int J Cancer. 2008 Sep 15;123(6):1246-54
references: 18566989
references: Ann Oncol. 2005 Jan;16(1):70-4
references: 15598941
references: Biochemistry. 2005 Jun 14;44(23):8418-27
references: 15938631
references: Nat Protoc. 2007;2(6):1350-5
references: 17545972
references: Nat Rev Cancer. 2006 May;6(5):360-8
references: 16633364
references: Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2860-8
references: 19843676
references: Science. 2002 Mar 29;295(5564):2465-8
references: 11923541
references: Int J Biol Markers. 2010 Oct-Dec;25(4):185-94
references: 21161939
references: Mol Oncol. 2007 Sep;1(2):138-43
references: 19383291
references: Am J Pathol. 2003 Dec;163(6):2259-69
references: 14633600
references: J Steroid Biochem Mol Biol. 1993 Nov;46(5):605-11
references: 8240983
references: Mol Endocrinol. 2002 Jan;16(1):70-84
references: 11773440
references: Science. 2005 Mar 11;307(5715):1625-30
references: 15705806
references: Cancer Res. 2009 Jul 1;69(13):5415-23
references: 19549922
references: Endocrinology. 1997 Dec;138(12):5605-17
references: 9389549
references: Carcinogenesis. 1996 May;17(5):1149-52
references: 8640926